Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

被引：202

作者：

Menter, A. ^{[1
]}

Papp, K. A. ^{[2
]}

Gooderham, M. ^{[3
]}

Pariser, D. M. ^{[4
,5
]}

Augustin, M. ^{[6
]}

Kerdel, F. A. ^{[7
]}

Fakharzadeh, S. ^{[8
]}

Goyal, K. ^{[8
]}

Calabro, S. ^{[8
]}

Langholff, W. ^{[9
]}

Chavers, S. ^{[10
]}

Naessens, D. ^{[11
]}

Sermon, J. ^{[11
]}

Krueger, G. G. ^{[12
]}

机构：

[1] Baylor Univ, Med Ctr, Dallas, TX 75246 USA

[2] K Papp Clin Res & Prob Med Res Inc, Waterloo, ON, Canada

[3] SKIN Ctr Dermatol & Prob Med Res, Peterborough, ON, Canada

[4] Eastern Virginia Med Sch, Norfolk, VA 23501 USA

[5] Virginia Clin Res, Norfolk, VA USA

[6] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[7] Florida Acad Dermatol Ctr, Miami, FL USA

[8] Janssen Sci Affairs LLC, Horsham, PA USA

[9] Janssen Res & Dev LLC, Horsham, PA USA

[10] Janssen Res & Dev LLC, Titusville, NJ USA

[11] Janssen Cilag NV, Beerse, Belgium

[12] Univ Utah, Sch Med, Salt Lake City, UT USA

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷 / 07期

关键词：

DOUBLE-BLIND; REAL-LIFE; ADALIMUMAB; DISCONTINUATION; USTEKINUMAB; ETANERCEPT; ARTHRITIS; MULTICENTER; SAFETY; COHORT;

D O I：

10.1111/jdv.13611

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

BackgroundDrug survival is a marker for treatment sustainability in chronic diseases such as psoriasis. ObjectiveThe aim of these analyses was to assess survival of biologic treatments in the PSOriasis Longitudinal Assessment and Registry (PSOLAR). MethodsPSOLAR is a large, prospective, international, disease-based registry of patients with psoriasis receiving (or eligible for) systemic therapy in a real-world setting. Drug survival is defined as the time from initiation to discontinuation (stop/switch) of biologic therapy on registry. The number of patients who discontinued each treatment and the duration of therapy were recorded. Using Kaplan-Meier survival curves and Cox-regression analyses [hazard ratios (HR) and 95% confidence intervals (CIs)], time to discontinuation was compared across cohorts undergoing first-, second- or third-line treatment with ustekinumab, infliximab, adalimumab or etanercept. ResultsAs of the 2013 data cut, 12 095 patients with psoriasis were enrolled in PSOLAR. Of the 4000 patients initiating any new biologic therapy, approximately 3500 started a first-line, second-line or third-line biologic therapy during the registry. Lack of effectiveness was the most common reason for discontinuation across biologic therapies. Based on the multivariate analysis, significantly shorter times to discontinuation were observed for infliximab [HR (95%CI) = 2.73 (1.48-5.04), P = 0.0014]; adalimumab [4.16 (2.80-6.20), P < 0.0001]; and etanercept [4.91 (3.28-7.35) P < 0.0001] compared with ustekinumab [reference treatment]) for first-line biologic use; results were similar for treatment effects for second/third-line therapies. Although limited in power, analyses in patients with concurrent psoriatic arthritis confirmed by a rheumatologist reflect observations in the overall psoriasis population. ConclusionDrug survival was superior for ustekinumab compared with infliximab, adalimumab and etanercept in patients with psoriasis. revised: 14 July 2015; Accepted: 6 January 2016

引用

页码：1148 / 1158

页数：11

共 30 条

[1]

[Anonymous], 2013, REM INFL PACK INS

[2]

[Anonymous], 2013, HUM AD PACK INS

[3]

[Anonymous], 2013, STEL UST PACK INS

[4]

[Anonymous], 2013, ENBR ET PACK INS